The results of these studies appear in the October 2005 issue of Liver Transplantation, the official journal of the American Association for the Study of Liver Diseases (AASLD) and the International Liver Transplantation Society (ILTS). The journal is published on behalf of the societies by John Wiley & Sons, Inc. and is available online via Wiley InterScience at http://www.interscience.wiley.com/journal/livertransplantation.
Hepatitis C is the leading cause of liver transplants and recurrence of the disease following transplant is a serious problem. It is estimated that up to 20 percent of HCV patients will develop fibrosis or cirrhosis within two years of undergoing a transplant. Antiviral therapy is not highly effective in transplant patients and poses additional problems for these individuals, who may have difficulty tolerating the potent drugs it involves. However, antiviral therapy might be useful for those patients likely to develop fibrosis, if they could somehow be identified. Hepatic stellate cells (HSC) normally store vitamin A in the liver, but in HCV patients these cells produce collagen and other proteins that can lead to fibrosis. Researchers tried to determine if HSC activation could help predict which patients would later develop fibrosis by using laboratory analysis of alpha smooth muscle actin (alpha-SMA), a reliable marker for HSC activation.
In one study, led by Samer Gawrieh of the Division of Gastroenterology and Hepatology at the Mayo Clinic Colleg
Contact: David Greenberg
John Wiley & Sons, Inc.